DBV Technologies Files 2025 Annual Report, Extends Runway as 2026 Peanut Patch Filings Near

Overview

• DBV Technologies said it filed its 2025 Form 10-K with the SEC and its 2025 Universal Registration Document with France’s AMF, with the URD covering the annual report, board governance, buy-back program, and auditor information.
• For 2025, the company reported $5.6 million in operating income and a $147.0 million net loss, driven by higher research spending tied to clinical programs and by added commercial planning costs.
• Management said $94 million raised from warrant exercises in January 2026, combined with year-end cash, should fund operations into the second quarter of 2027.
• The company completed enrollment in its COMFORT Toddlers safety study and plans to submit a BLA for children ages 4 to 7 in the first half of 2026 with potential Priority Review, followed by a BLA for ages 1 to 3 in the second half under an Accelerated Approval path.
• VIASKIN uses a small patch to deliver microgram amounts of peanut protein through the skin to train the immune system, which could offer a noninvasive option for families managing peanut allergy if regulators approve it.